KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Leases (2019 - 2025)

Halozyme Therapeutics (HALO) has disclosed Leases for 8 consecutive years, with $37.7 million as the latest value for Q4 2025.

  • Quarterly Leases rose 10.31% to $37.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.7 million through Dec 2025, up 10.31% year-over-year, with the annual reading at $37.7 million for FY2025, 10.31% up from the prior year.
  • Leases for Q4 2025 was $37.7 million at Halozyme Therapeutics, up from $30.8 million in the prior quarter.
  • The five-year high for Leases was $40.5 million in Q4 2022, with the low at $1.6 million in Q1 2022.
  • Average Leases over 5 years is $24.4 million, with a median of $33.4 million recorded in 2024.
  • The sharpest move saw Leases tumbled 49.27% in 2022, then soared 2410.83% in 2023.
  • Over 5 years, Leases stood at $2.0 million in 2021, then surged by 1920.42% to $40.5 million in 2022, then decreased by 8.98% to $36.8 million in 2023, then dropped by 7.23% to $34.2 million in 2024, then increased by 10.31% to $37.7 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $37.7 million, $30.8 million, and $31.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.